galm pharmaceut ltd glmd hold downgrad hold arriv trial miss primari endpoint hiv associ
adami pharmaceut corpor admp buy pt adjust time increas risk rate
result price fall analyst jason kolbert full summari
quantum genom sa alqgc pa buy pt lower price quantum travers data
trough data analyst jason kolbert full summari
immutep limit immp buy pt lower price could checkpoint
take time get analyst jason kolbert full summari
 buy pt lower pt remov hiv model focu
catalyst infecti diseas pipelin analyst jason kolbert full summari
inc buy pt ev/ni product revenu acceler y/i growth reiter
snoa buy pt adjust model busi develop result chang
price fall analyst jason kolbert full summari
sophiri inc sph buy pt increas risk assumpt lower price
xtant medic hold inc xtnt buy pt reduc pt split-adjust convert note
restructur strengthen balanc sheet analyst anthoni vendetti full summari
inc hold result better expect guidanc estim stock fairli
ellington llc buy pt continu progress toward dividend coverag reiter buy
rate price analyst michael diana full summari
inc sb buy pt earn first look result well-ahead estim consensu
corpor event call maxim salesperson inform
landec corpor cover vendetti ndr boston cfo greg skinner tue feb
dineequ inc cover ndr san francisco ceo stephen joyc interim cfo gregori
kalvin execut director ir ken dipte mon feb
cover ndr boston cfo golder wed jun
keyw hold corp keyw cover kinstling ndr san francisco ceo weber wed thu feb
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
corp cover kinstling ndr boston cfo ranjan kalia wed
payment data system inc pyd host kinstling ndr nyc ceo loui hoch cfo tom jewel
result better expect guidanc
estim stock fairli valu reiter
total revenu y/i estim
consensu north america product revenu grew
y/i intern product revenu grew y/i
non-gaap ep y/i estim
consensu ep y/i primarili due
impact relat tax reform exclud ep in-line
estim consensu
full-year guidanc revenu
gaap ep prior estim consensu
announc addit juliet secret rf devic
product portfolio manufactur third parti
bottom line would initi new posit despit report better-
than-expect result introduc guidanc estim
consensu maintain belief compani fairli valu current
level expect y/i revenu growth deceler next two year
compani face tougher comp view could drive perform
expect innov new product launch howev awar
game-chang product pipelin believ technolog
regulatori clearanc behind juliet secret rf provid signific differenti
result summari yesterday market close report
total revenu y/i estim
consensu north america product revenu y/i
intern product revenu y/i non-gaap gross
margin y/i estim consensu
non-gaap ep y/i estim
consensu ep y/i primarili due
impact relat tax reform exclud ep in-line
estim consensu compani repurchas approxim
share fulli util current share buy-back plan
finish year cash equival market
invest debt
repres y/i growth rang new
estim prior estim consensu
moreov compani introduc non-gaap ep guidanc
y/i increas rang in-line new estim
prior estim consensu final expect
adjust ebitda bracket new estim
prior estim consensu
rais estim due better-than-expect result guidanc rais
full-year revenu estim
respect also rais full-year ep
estim respect
valuat share current trade ev/revenu estim compar
peer averag
click full note
earn first look result well-ahead
result well-ahead estim oper ep
versu estim loss per share
net revenu million ebitda million higher
expect million million respect
consensu estim net revenu million ebitda
beat mainli attribut higher util level rate
achiev compani panamax fleet achiev fleet-wid tce
rate per vessel/day
previous announc sb taken deliveri
panamax vessel agio spyridona vessel current trade
short-term charter per/day
sb took million impair charg relat four
result came well-ahead expect sb report strong
earn suspect increas dri bulk demand notabl
coal grain iron ore believ strong harvest session coupl
increas far east asian coal demand quarter help sb return
profit ahead forecast
net revenu actual vs maxim consensu
ebitda actual vs maxim consensu
oper ep actual vs maxim consensu
fleet updat januari compani took deliveri panamax vessel
sister-ship two panamax vessel vessel current oper
short-term charter end per day expect sb realiz
oper cost save sister vessel
overhang newbuild financ sb current one kamsarmax vessel set
deliveri approxim million remain final
vessel payment end sb secur million prefer
equiti financ addit liquid avail anticip roadblock
vessel ad fleet compani also adequ cash
balanc million
impair charg compani took million impair charg
relat four panamax vessel
question call
dri bulk market seemingli upturn continu charter
strategi look spot leverag year
come chines new year rate remain strong overal
panamax segment segment lead way kamsarmax
mix cargo coal/grains/iron ore
largest demand region
still opportun market accret acquisit
look expand fleet
click full note
ev/ni product revenu acceler
product revenu acceler y/i growth
bear concern regard januari quarter result weak view make
ev/ni multipl attract entri point
midpoint guidanc impli product revenu y/i
uniqu hybrid cloud data manag capabl align mega-
reiter buy rate slightli rais dcf-base price target
product revenu acceler y/i growth report januari quarter
revenu y/i midpoint guidanc
impli book y/i acceler y/i jul
 importantli product revenu y/i consensu
acceler y/i product revenu growth octob
 balanc sheet driven revenu item softwar entitl mainten
y/i servic revenu y/i larg in-
line above-consensu estim though believ mis-
calibr consensu estim note track defer revenu
instal base assum four year refresh cycl tick y/i indic
better execut sign servic contract notabl strateg solut
product revenu acceler y/i past ten quarter averag
y/i growth matur solut declin stabil flat y/i manag
also note competit san displac continu two
quarter ago product gross margin y/i
estim better past year season declin q/q
actual declin q/q ep beat consensu estim
manag note without favor tax rate chang currenc gain
non-gaap ep would
bear concern regard januari quarter result weak view make
ev/ni multipl attract entri point note after-market price
quot share trade ev/ni consensu
estim believ follow bear concern heard investor
regard januari quarter result caus concern product gm
q/q servic revenu continu declin y/i dso day y/
howev believ concern weak present attract entri
point given product gm jan typic q/q
high-margin feder deal shift q/q feder budget flush septemb
defer revenu instal base ratio continu tick use year life-cycle
assumpt indic declin mere result prior year y/i declin
manag note linear similar prior year increas
dso due time issu associ channel believ mean
faster pay channel busi weight toward end
quarter wherea slower pay larg enterpris account front-end load
midpoint guidanc impli product revenu y/i
consensu midpoint april quarter revenu guidanc y/i
consensu estim midpoint ep guidanc
in-lin consensu estim note midpoint guidanc impli
product revenu y/i full rang y/i growth q/q
increas modestli higher past year averag q/q
uniqu hybrid cloud data manag capabl align mega-multi-
year trend continu believ driver increas busi momentum
least partial result larg matur portfolio hybrid cloud data manag
product netapp privat storag releas late ontap cloud launch
late altavault acquir cloudsync cloud control
releas late align hybrid cloud trend differenti
manner much way align virtual trend
product gm
reiter buy rate slightli rais dcf-base price target
per august upgrad continu believ well
posit continu expand oper margin high end
om guidanc consensu maxim also
note manag announc analyst day held april nyc
estim slightli increas result dcf-base price target rise
slightli key assumpt includ multipl acquisition-
adjust assum util acquisit consist prior five-
year averag termin period chang defer revenu driven
zero termin period ensur equilibr non-gaap net incom
wacc
click full note
downgrad hold arriv trial miss primari endpoint
hiv associ lipodystrophi
glmd announc top-lin result arriv trial
meet primari endpoint recal arriv studi investig
led phase iia studi random double-blind placebo-
control studi treat patient week goal establish
proof-of-concept poc aramchol versu placebo
patient hiv-associ lipodystrophi nafld primari endpoint
studi improv liver fat week measur mri-
pdff liver biopsi includ part evalu pilot
unfortun trial show differ hiv patient receiv
aramchol week compar hiv patient placebo arm
aramchol show favor safeti toler profil
top-lin data galm phase iib arrest studi nash patient
assess aramchol follow week treatment
endpoint measur mr liver biopsi expect
next major event compani
conclus failur hiv patient neg necessarili
mean aramchol fail arrest studi said binari
event predict confid result believ lower
rate hold buy remov price target prudent risk advers
investor may choos exit stock versu wait data next quarter
hiv patient advanc liver diseas appear differ mechan
action multi-factori pathogeni involv hiv lipodystrophi nafld
liver diseas hiv infect patient due complex mix
uniqu common etiolog sherman et al hepatolog
data recent publish highlight circumst uniqu hiv
infect patient may contribut develop nafld nash
hardi et al annurev pathol tafesh et al current opinion
hiv lipodystrophi patient underli fat destruct may differ
featur seen common nash addit medic
specif treatment hiv may lead fatti acid accumul via varieti
pathway hiv viru directli cytotox liver cell via hiv signal
variou factor may contribut lack effect seen
patient includ complex pathogenesi heterogen popul
well character moa aramchol target pathway involv common
nash regul improv fatti acid oxid direct effect
fibrosi arrest studi enrol popul common nash patient
dietari main sourc fatti acid liver therefor expect
demonstr benefici effect aramchol mr liver biopsi
click full note
lower price quantum
travers data trough data
quantum valuat current low end rang due
lack catalyst see data trough continu
compani recent initi phase studi
bapai brain aminopeptidas inhibitor expect data
made sever adjust model major one
increas risk adjust hypertens line
risk rate use heart failur better account
risk earli stage develop lower price target
phase studi new-hop hypertens underway
trial expect enrol patient due complet
data expect report hypertens studi lead
program quantum remain driver compani
expect data patient studi heart failur hf
see increment catalyst
quantum cash balanc sheet
suffici runway current per quarter burn rate
howev might see rais hf later year alway tri
balanc cash versu catalyst
conclus quantum continu advanc bapai platform
hypertens heart failur new-hop studi continu
enrol data expect see data heart failur
studi increment combin quantum data trough given
current valuat compani believ prudent lower
bapai brain blood pressur control bapai new class drug
target brain renin-angiotensin-aldosteron system raa bapai target
enzym aminopeptidas convert angiotensin ii ang ii angiotensin
ang ang main effector peptid brain raa exert stimulatori
control blood pressur brain raa differ raa peripheri
avail drug target act central control regul blood
diuret class bapai penetr brain tripl
effect lower vasopressin lower sympathet nerv activ increas baroreflex
net result increas diuresi urinari elimin lower vascular resist
control heart rate bapai potenti use monotherapi
combin avail drug anti-hypertens cardio-
target patient poorli control blood pressur twenti
percent patient poorli control blood pressur resist
multipl drug current avail mani patient low renin high
vasopressin lrhv target brain raa versu peripheri
potenti control blood pressur patient combin
current approv therapi could provid effect well-toler
approach treat high blood pressur chronic heart failur novel combin
approach includ bapai could expand hypertens heart failur drug
market view new european ip cover combin therapi
multipl medic wide prescrib treat hypertens heart
click full note
lower price could
checkpoint take time get
maintain posit view space progress
immutep make develop pipelin go take time
capit given earli stage trial breast cancer melanoma
extend timelin approv specif anticip
commerci breast cancer europ
 chang combin
model adjust result price target reduc
addit note compani cash balanc sheet
current burn rate per quarter suffici runway
expect see capit rais point year
compani expect provid data updat
trial melanoma keytruda studi breast
cancer chemotherapi posit repres catalyst
higher valuat and/or opportun rais capit higher valuat
could also see data updat partner novarti nv nr
glaxosmithklin gsk nr respect though
time disclos
earli data thu far breast cancer melanoma
posit fundament posit bia potenti
space remain continu believ like next
checkpoint emerg pair like
immunotherapi go take time capit establish definit
proof concept
immutep lead candid develop immun
adjuv immun stimul solubl dimer recombin form
fusion protein use increas immun respons tumor
stimul dendrit cell high affin bind mhc class ii molecul
dendrit cell surfac one two protein shown abl properli
condit dendrit cell monocyt undergo matur step
stimul antigen target t-cell ligand what import
note without inflamm
develop dr frdric triebel late dendritic-cel activ
use low dose use t-cell adjuv cancer vaccin
higher dose combin cancer chemotherapi ramp
immun respons drive dendrit cell monocyt increas tumor antigen
larg indic right partner novarti licens
develop combin therapi inhibitor solid tumor on-going
clinic studi multipl cancer type januari expand enrol
anoth patient novarti also initi anoth program
hematolog solid cancer combin inhibitor gsk
evalu phase studi psoriasi trial expect complet
march immutep receiv single-digit royalti partnership lead
in-hous program antigen-pres cell apc activ ramp
t-cell product follow chemotherapi alreadi demonstr poc breast cancer
current phase iib registr studi could launch phase
studi combin keytruda melanoma patient also posit
far demonstr tumor reduct patient
click full note
lower pt remov hiv
model focu catalyst infecti diseas
pipelin
model valuat inovio mainli driven program immune-
oncolog program infecti diseas id includ ebola mer zika
hepb hiv earlier stage develop assign valu
vaccin yet hiv hiv still viabl program
other remov hiv model consist
lack valu assign vaccin mention
chang lower price target
stock weak inovio share trade low-end
rang due sever factor signific drop valuat
occur follow capit rais price discount
juli close price howev lack catalyst
remaind data trough may factor
downward pressur good news inovio cash
balanc sheet suffici runway addit
compani lead asset on-going program cervic
increment catalyst lay ahead infecti diseas expect
see data infecti diseas pipelin includ studi
vaccin hepb ebola mer zika hiv also look
initi first clinic program data dna-bas monoclon
antibodi could see data sever studi
immune-oncolog head neck cervic bladder gbm like
data event data pivot program key event
conclus lower price target still
repres signific upsid expect multipl infecti
diseas program continu advanc report data provid
increment catalyst stock wait data immune-
pivot studi program includ two studi reveal
reveal patient cin cervic intraepitheli neoplasia
associ hpv type across studi center global manufactur
scale commerci cellectra electropor devic
readi go reveal studi random two one double-blind
placebo-control remind target protein hpv
viru patient studi receiv intramuscular electropor
cellectra day placebo cellectra primari endpoint
studi percent patient evid cervic high grade squamou
intraepitheli lesion histolog evid and/or
week phase ii studi treatment result histopatholog
regress diseas meet studi primari endpoint
addit trial demonstr clearanc hpv conjunct regress
click full note
increas risk assumpt lower price target
sake conservat rais therapeut risk cut
market opportun innov new treatment prostat
cancer larg use model predict outcom next clinic phase
develop difficult imposs increas risk cut
model result price target fall
sophiri recent announc complet enrol phase
studi evalu safeti toler topsalysin treat men
sophiri expect biopsi data patient dose first
administr topsalysin avail first half
phase studi includ option re-treat patient second dose
topsalysin target biopsi occur week follow second
dose compani expect complet data patient receiv
second dose assum enrol complet expect
remind studi target patient safeti
toler assess week post-treat efficaci
evalu week via biopsi imag
remind studi local prostat cancer six month
topsalysin ablat tumor cell patient includ two experienc
complet tumor ablat view data repres proof concept
studi build upon poc data demonstr
studi also see respons enhanc second dose
time well optim deliveri
conclus see topsalysin new paradigm physician pc
armamentarium predict success math-bas model near
imposs increas therapeut risk cut
lower price target
indic prostat cancer topsalysin seek destroy
psa-express cell prostat opportun beyond bph
prostat cancer directli inject prostat cancer lesion mechan
action drill hole psa-express cell caus cell death could provid
focal therapi local prostat cancer avoid complic side
effect surgeri direct inject cancer lesion prostat allow
sophiri visual tumor shrinkage/abl via mri imag histolog stain
control local diseas shown minim metastasi opportun
larg new case prostat cancer
prostat cancer studi studi multi-cent open-label evalu
topsalysin local prostat cancer studi enrol patient
uk mri imag map ultrasound guid target deliveri
topsalysin pre-identifi tumor safeti evalu week post-
treatment efficaci evalu biopsi imag week six-month
biopsi data expect patient experi posit safeti profil
tumor ablat clinic meaning tumor remain
option second dose abl see repeat dose
time enhanc topsalysin effect
click full note
reduc pt split-adjust convert
note restructur strengthen balanc sheet
xtnt expect complet restructur convers roughli
outstand convert note common equiti end today
compani also effect revers stock split market open
expect complet privat placement debt-hold ro
orbim end today
estim compani cash balanc roughli follow
transact ro orbim own outstand
common stock outstand debt accru interest
xtnt also expect launch right offer
bottom line would continu buyer xtnt remov part
debt overhang restructur convert outstand convert note
common share transact would result major dilut expect
compani benefit financi oper interest burden reduc
uncertainti surround solvenc somewhat mitig howev compani
would still roughli outstand debt accru interest
interest rate believ potenti restructur oblig repres next
final step elimin debt overhang hamper compani sinc
acquisit x-spine system juli
restructur agreement januari xtnt announc enter
restructur exchang agreement ro orbim holder
convert note agreement includ number transact mani
need sharehold approv reform capit structur meet liquid need
regain complianc nyse american list standard yesterday special
meet stockhold major sharehold approv propos tier
transact expect complet today see page detail
effect transact follow transact ro orbim would
collect compani outstand common stock
convert notehold would aggreg xtnt also note
payabl outstand ro orbim estim princip
unpaid accru interest outstand note accru interest annual rate
plu greater libor payabl quarterli payabl
kind matur juli estim roughli post-transact cash
equival expect compani regain complianc nyse american
list standard februari deadlin
reduc estim due elimin convert note lower
interest expens estim also adjust estim weight
averag share outstand reflect issuanc addit share
convers final alter histor project share count reflect
revers split therefor widen
ep loss estim
valuat due aforement factor reduc price target
split-adjust new price target base dcf analysi
use discount rate perpetu growth rate xtnt current trade
ev/revenu estim compar peer averag
price target impli share trade ev/revenu estim still
significantli industri averag
click full note
adjust model busi develop result
chang price fall
adjust outyear model assumpt lower
compani product result chang price target fall
also take note fact compani last
report quarter cash balanc sheet may need
rais capit sometim year depend revenu perform
forecast break-even sever year need rais capit creat
overhang micro-cap stock sonoma addit
risk factor highlight
last week manag guid indirectli think higher growth
rate us dermatolog busi versu rest world slower growth
mid-singl digit telephone-bas market appear impact
manag highlight next area focu manag also
highlight revenu compani reach break-even
conclus one strongest quarter howev believ
prudent reduc outyear assumpt also close watch
busi highlight recent quarter
sonoma market six non-steroid product treatment atop
seborrh dermat surgic procedur sever acn skin repair descal
scar manag
sonoma dermatology-focus sale repres
prior period five sale manag focus exclus dermatolog
receiv approv brazilian ministrio da sade seven non-steroid
non-antibiot topic dermatolog product octob
receiv approv unit arab emir uae ministri prevent
three product daili eyelid hygien antimicrobi nasal clean
antisept mouth throat rins
receiv two fda clearanc add antimicrobi languag alevicynsg
spray gel alevicyn dermal spray solut label chang
differenti alevicyn topic steroid addit antimicrobi properti
alevicyn offer altern use antibiot manag infect
associ atop dermat
product launch loyon skin descal product approv fda march
load wholesal septemb promot sale
rep begin late novemb
china sonoma work two commerci partner distribut acut
care product plan enter larger dermatolog product space countri
sonoma make effort build revenu multipl new product launch
eight pipelin includ innov descal product loyon highlight
launch quarter modest price increas continu
expans dermatolog sale forc
click full note
adjust time increas risk rate
result price fall
recent news launch develop
associ symjepi result increas therapeut risk
cut epinephrin pre-fil syring model commerci
assumpt addit also pushing-out time back
pipelin product model includ
inhal result chang price target fall
remain hope see deal soon estim adami
speak multipl potenti partner commerci symjepi
compani version epipen also look deal term
superior given fact approv product recal
prior deal watson gener divis allergan nr
propos payment combin up-front regulatori
perform mileston well doubl digit royalti sale
pipelin heard much compani around pipelin
product hfa inhal steroid hfa albuterol
taper dri powder inhal result pushing-out
commerci time
compound pharmaci progress hope see steadi progress
assum acquisit work compani complet
process integr quarterli report provid import look
busi
new product platform technolog need simpl user friendli self-
inject devic rise see potenti compani develop
indic focu opioid crisi
mayb new opportun pfs-like product save live yet
factor revenu beyond symjepi
adami announc fda approv epinephrin inject
usp pre-fil single-dos syring emerg
treatment allerg reaction type includ anaphylaxi fda also
approv trade name symjepi
symjepi provid two singl dose syring epinephrin adrenalin
consid drug choic immedi administr acut anaphylact
reaction insect sting bite allerg reaction food nut drug
allergen well idiopath exercise-induc anaphylaxi
second submiss happen junior version
symjepi manag comment product provid patient
addit therapeut choic lower cost small size user-friendli design
click full note
continu progress toward dividend coverag
reiter buy rate price target
report ep versu dividend
maintain ep estim price target
price target equat book valu view mortgag reit
trade valuat level book valu
result summari yesterday post-clos report ep
versu dividend book valu per share
book valu per share aid share buyback ad per share
continu non-agency/credit strategi contribut
agenc strategi contribut expens
leverag increas equiti long credit/non-ag
portfolio increas increas attribut placehold asset
yield one-half core asset ad increas net interest
incom expect replac core asset mostli non-commodit
new busi model european bank divest credit/non-ag
asset due basel sinc year-end decreas non-ag
long credit portfolio increas credit
asset class mostli non-commodit loan transit
increas net interest incom count support dividend
speed transit transit implement quickli reli
prudent direct origin heighten competit credit asset
transit slower anticip though manag still expect
portfolio reach level suffici support dividend coverag
maintain ep estim could one two quarter
soon dividend coverag net interest incom expect current
environ volatil present opportun
gener trade profit page updat earn model
maintain price target price target equat book valu
view mortgag reit trade valuat level
book valu current environ note disclos januari
book valu adjust one-third dividend payment
would impli interim book valu far
reiter buy rate next four quarter expect dividend
yield stock price appreci price target
result estim total return share
recent disappoint investor us strategi appear
posit succeed view
new tax law new tax law give preferenti tax treatment distribut reit
includ mortgag reit non-reit tax partnership distribut
sharehold capit gain return capit continu
tax ordinari incom wherea distribut mortgag reit sharehold
tax ordinari incom rate addit manag
indic evalu could make sens chang structur
click full note
despit disrupt florida texa weather job post
adjust ebitda million quarterli record
low unemploy rate favor temporari staf industri
job well-posit benefit trend
larg profession staf compani recent highlight
improv stronger urgenc complet discretionari project
improv busi optim contribut stronger staf demand
adjust ebitda estim larg unchang million
million
trade ev/adjust ebitda base estim
believ job share attract
job post strongest quarterli profit histori dec report
morn adjust ebitda million higher estim
revenu million million lower estim due weather-
relat disrupt florida texa howev signific cost cut effort due
sever complet acquisit like redund led all-tim high
oper margin also aid profit favor revenu mix
job gener million direct placement revenu million
profession contract servic gross margin servic quarter
respect meanwhil low-margin industri servic segment
gener revenu million gross margin quarter
industri staf repres revenu
mainli due sni acquisit line manag strategi
improv profit
expect integr sni recoveri florida texa lead
stronger adjust ebitda although florida texa oper
fulli recov march quarter expect season payrol
tax result weakest adjust ebitda basi howev
lower sg decemb quarter strengthen demand trend staf
lead even stronger profit opinion manag highlight
expect continu benefit low unemploy rate skill profession
worker echo sentiment staf compani nr
expect addit acquisit anoth six nine month
staf industri consolid year manag clear
intend grow profession staf segment acquisit believ
integr sni almost complet job focu improv profit
exist busi job plan use stock cash acquisit view
post quarter stronger profit lead higher stock price
creat stronger acquisit currenc howev current stock price given
debt relat sni acquisit activ unlik anoth six nine month
reiter buy rate price target share current trade
ev/adjust ebitda base estim price target assum ev/
ebitda valuat expect realiz job result continu
strengthen valuat assum roughli five million share prefer
common stock convert
click full note
maxim analyst coverag univers
